Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

CNS Spectrums

Volumn 17, Issue 3, 2012, Pages 155-163

  Katsuki, Asuka ^a   Yoshimura, Reiji ^a   Kishi, Taro ^b,c   Hori, Hikaru ^a   Umene Nakano, Wakako ^a   Ikenouchi Sugita, Atsuko ^a   Hayashi, Kenji ^a   Atake, Kiyokazu ^a   Iwata, Nakao ^c   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3 methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Homovanillic acid; Major depressive disorder; Mirtazapine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; HOMOVANILLIC ACID; MIRTAZAPINE; NEUROTROPHIN 3; NEUROTROPHIN 4;

ADULT; AGED; AKATHISIA; ARTICLE; BDNF GENE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERPHAGIA; HYPOMANIA; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHYLENE GLYCOLS; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHIONINE; MIANSERIN; MIDDLE AGED; PHENOLS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; VALINE; YOUNG ADULT;

EID: 84869232094     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291200051X     Document Type: Article

References (35)

1. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 2005; 10(suppl 4): 19-23.
2. De Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs. 1995; 4: 13-17.
3. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997; 54(7): 597-605.
4. Rogoz Z, Skuza G, Legutko B. Repeated treatment with mirtazapine induced brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol. 2005; 56(4): 661-671.
5. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002; 109(2): 143-148.
6. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1): 70-75.
7. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2): 261-265.
8. Gonul AS, Akdeniz F, Taneli F, et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6): 381-386.
9. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008; 64(6): 527-532.
10. Brunori AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008; 11(8): 1169-1180.
11. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analysis. World J Biol Psychiatry. 2010; 11(6): 763-773.
12. Mowla SJ, Pareek S, Farhadi HF, et al. Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci. 1999; 19(6): 2069-2080.
13. Kang RH, Chang HS, Wong ML, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol. 2010; 24(12): 1755-1763.
14. American Psychiatric Association. A text revision of Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington, DC: American Psychiatric Association; 2000.
15. First MB, Spitzer RL, Gibbon M, Williams JBW. The Structured Clinical Interview for DSM-III-R personality disorders (SCID-II, Version 2.0): part I: description. J Personal Disord. 1995; 9: 83-91.
16. Umene-Nakano W, Yoshimura R, Ueda N, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2010; 24(12): 1764-1771.
17. Yeung PK, Buckley SJ, Pedder SC, et al. Determination of 3,4-dihydroxyphenylacetic acid and 5-dihydroxyphenyleacetic acid in human plasma by a sample and rapid high-performance liquid chromatography assay. J Pharm Sci. 1996; 85(4): 451-453.
18. Minegishi A, Ishizaki T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984; 311(1): 51-57.
19. Wolkowitz OM, Wolf J, Shellty W, et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1623-1630.
20. Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Higher plasma interleukin-6 (IL-6) level is associated with SSRIor SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(4): 722-726.
21. Yoshimura R, Mitoma M, Sugita A, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1034-1037.
22. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1): 70-75.
23. Satomura E, Baba H, Nakano Y, et al. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord. 2011; 135(1-3): 332-335.
24. Jevtovic S, Kariovic D, Mihaljevic-Peles A, et al. Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub. 2011; 23(4): 363-369.
25. Birkenhager TK, Geldermans S, Van den Broek WW, et al. Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res. 2012; 46(3): 284-289.
26. Zhang Y, Gu F, Chen J, et al. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res. 2010; 1366: 141-148.
27. Devoto P, Flore G, Pira L, et al. Mirtazapine-induced correlate of dopamine and noradrenaline from noradrenergic neurons in the prefrontal and occipital cortex. Eur J Pharmacol. 2004; 487(1-3): 105-111.
28. Delgado PL, Moreno FA, Onate L, et al. Sequential catecholamine and serotonin depletion in mirtazapinetreated depressed patients. Int J Neuropsychopharmacol. 2002; 5(1): 63-66.
29. Yoshimura R, Kishi T, Suzuki A, et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(4): 1022-1025.
30. Zou YF, Ye DQ, Feng XL, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 2010; 20(8): 535-544.
31. Zou YF, Wang Y, Liu P, et al. Association of brain-derived neurotrophic factor gene Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiol. 2010; 61(2): 71-78.
32. Chi MH, Chang HH, Lee SY, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord. 2010; 126(3): 430-435.
33. Ozan E, Okur H, Eker OD, et al. The effect of depression, BDNF val66met polymorphism and gender on serum BDNF levels. Brain Res Bull. 2010; 81(1): 61-65.
34. Terracciano A, Martin B, Ansari D, et al. Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav. 2010; 9(5): 512-518.
35. Kendler KS, Myers J, Zisook S. Does bereavementrelated major depression differ from major depression associated with other stressful life events? Am J Psychiatry. 2008; 165(11): 1449-1455.